EBOS delivers record first-half earnings
EBOS Group today announced a record interim unaudited net profit of $76.7 million for the six months to 31 December 2017, demonstrating the benefits of a diverse portfolio of Healthcare and Animal Care businesses in Australia and New Zealand.
- Group revenue stable at $3.9 billion
- EBITDA growth of 15.6% (+9.5% underlying, constant currency basis)
- Net Profit after Tax up 11.5% (+5.5% underlying, constant currency basis)
- Record first half Operating Cashflow of $101.7 million
- Earnings per Share growth of 11.0% (+7.4%, constant currency basis)
- Interim dividend declared of 33 cents per share, +10% to the previous corresponding period
“Our record first half results are in line with our expectations and reflect a consistent positive momentum across both our Healthcare and Animal Care businesses”, said CEO, Patrick Davies.
“During the first half, we have fully transitioned HPS into the Group, further expanding our leading position in the Institutional Healthcare market. In October, we acquired a strategic 14.1% shareholding in MedAdvisor Ltd, Australia’s leading digital medication management company.
“Of equal importance to our investment in new businesses is the organic growth we are seeing across our diversified portfolio. Our Animal Care segment continues to perform strongly and in July 2017 Black Hawk was launched in New Zealand with excellent retail support.
“In Healthcare, the rebranding of TerryWhite and Chemmart pharmacies to TerryWhite Chemmart is now largely complete. Red Seal continues to outperform in the New Zealand domestic market and is focused on growing into the Australian and Asian markets”, Mr Davies said.
“Our major capital projects in both Australia and New Zealand have all seen excellent progress over the period and remain on-track and budget. These investments are a key part of our strategy to provide the most efficient warehousing and distribution facilities for our expanding portfolio of businesses.”